AMINEPTINE SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H26NO2.Na
Molecular Weight	359.4371
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[O-]C(=O)CCCCCCNC1C2=CC=CC=C2CCC3=C1C=CC=C3

InChI

InChIKey=RXWWSYJKVIBAAU-UHFFFAOYSA-M

InChI=1S/C22H27NO2.Na/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22;/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C22H26NO2
Molecular Weight	336.4473
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-08/stablon_ct_10411_12029.pdf | www.ncbi.nlm.nih.gov/pubmed/21584062

Amineptine is a selective inhibitor of dopamine reuptake. The drug was developed in France and was marketed for the treatment of depressive disorders under the name Survector among the others. Amineptine was withdrawn from the French market in 1999 because of abuse and drug dependence and because of its hepatic (cholestatic injuries) and cutaneous (acne) adverse effects.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine transporter 180 Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21584062	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Major depression 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21584062	Primary		Withdrawn	Survector Approved Use Survector 100mg tablet is used in the treatment of depression. Launch Date 2.52460794E11

PubMed

Title	Date	PubMed
[The problem of side-effects: cardiotoxicity (author's transl)].	1981	7318761
[A study of three potential antidepressants (amineptin, mianserin and nomifensin) on the cardiovascular system and isolated intestine (author's transl)].	1982 Jun 10	6287607
[Hepatitis due to amineptin. 4 cases].	1982 Nov	7152212
[Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases].	1988	2977080
[Acne induced by amineptin: adnexal toxiderma].	1996	9636770
[A case of Parkinson syndrome secondary to combined amineptine and bromazepam abuse].	1998 Sep-Oct	9850824
Treatment for amphetamine withdrawal.	2001	11687170
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.	2001	11229449
Acneiform eruption caused by amineptine. A case report and review of the literature.	2001 Jul	11730047
Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme.	2001 Mar	11316923
Dopaminergic augmentation of sleep deprivation effects in bipolar depression.	2001 Nov 30	11728613
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.	2002 Dec	22034388
Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence.	2003	12495364
Fluoxetine dependence in a former amineptine abuser.	2004 Oct-Dec	15764428
Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation with molybdenum and thiocyanate.	2006 Dec	16829178
[A case of tianeptine abuse].	2006 Spring	16528638
Is it possible to be dependent to Tianeptine, an antidepressant? A case report.	2007 Apr 13	17270334
Utility of 7,7,8,8-tetracyanoquinodimethane charge transfer reagent for the spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides.	2007 Dec 31	17376736
Addressing the paradoxes of satisfaction with hospital care.	2008	19055265
Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse.	2008 Sep	18636997
Spectroscopic and electrochemical analysis of psychotropic drugs.	2009 Jan	20177449
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Research on antidepressants in India.	2010 Jan	21836704

Patents

Sample Use Guides

In Vivo Use Guide

Patients receive 200 mg of amineptine (survector) daily, in two divided doses at 8 A.M. and 12 noon for 6 weeks.

Route of Administration: Oral

In Vitro Use Guide

Rat neurones were treated with 300 nM-30uM of amineptine. Amineptine (1-30uM) decreased spontaneous firing and slightly hyperpolarized the membrane potential. At 300 nM-30uM amineptine increased the amplitude and duration of responses to exogenously applied dopamine.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:19:13 UTC 2023` Edited by `admin` on `Fri Dec 15 17:19:13 UTC 2023`
Record UNII	6BYR55117P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMINEPTINE SODIUM

Common Name

English

7-((10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)AMINO)HEPTANOIC ACID, SODIUM SALT

Common Name

English

Amineptine sodium [WHO-DD]

Common Name

English

HEPTANOIC ACID, 7-((10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)AMINO)-, SODIUM SALT (1:1)

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID70219006